Predictors of bleeding and time dependence of association of bleeding with mortality: Insights from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 (TRITON-TIMI 38)

Circulation

Volumn 123, Issue 23, 2011, Pages 2681-2689

  Hochholzer, Willibald ^a   Wiviott, Stephen D ^a   Antman, Elliott M ^a   Contant, Charles F ^a   Guo, Jianping ^a   Giugliano, Robert P ^a   Dalby, Anthony J ^b   Montalescot, Gilles ^c   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MILPARK HOSPITAL   (South Africa)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

clopidogrel; hemorrhage; mortality; prasugrel

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SEX; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STATISTICAL ANALYSIS;

AGED; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK FACTORS; THIOPHENES; THROMBOLYTIC THERAPY; TICLOPIDINE;

EID: 79959556568     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.002683     Document Type: Article

References (23)

1. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100:1261-1275. (Pubitemid 46742917)
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345: 494-502. (Pubitemid 32758501)
3. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354: 1706-1717.
4. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913. (Pubitemid 36736631)
5. Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-2564. (Pubitemid 40740853)
6. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Buttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742-1750. (Pubitemid 44648629)
7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. (Pubitemid 350106708)
8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
9. Unger EF. Weighing benefits and risks: the FDA's review of prasugrel. N Engl J Med. 2009;361:942-945.
10. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation. 2010; 122:394-403.
11. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
12. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782. (Pubitemid 44268228)
13. Mehran R, Pocock SJ, Stone GW, Clayton TC, Dangas GD, Feit F, Manoukian SV, Nikolsky E, Lansky AJ, Kirtane A, White HD, Colombo A, Ware JH, Moses JW, Ohman EM. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457-1466.
14. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200-1206. (Pubitemid 41505393)
15. Wiviott SD, Antman EM, Gibson CM, Montalescot G, Riesmeyer J, Weerakkody G, Winters KJ, Warmke JW, McCabe CH, Braunwald E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635. (Pubitemid 44396884)
16. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
17. Mortensen J, Thygesen SS, Johnsen SP, Vinther PM, Kristensen SD, Refsgaard J. Incidence of bleeding in 'real-life' acute coronary syndrome patients treated with antithrombotic therapy. Cardiology. 2008;111: 41-46.
18. Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, Madsen JK, Hansen PR, Kober L, Torp-Pedersen C, Gislason GH. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974.
19. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1607-1621.
20. Bellemain-Appaix A, Brieger D, Beygui F, Silvain J, Pena A, Cayla G, Barthelemy O, Collet JP, Montalescot G. New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. J Am Coll Cardiol. 2010;56:1542-1551.
21. Ducrocq G, Wallace JS, Baron G, Ravaud P, Alberts MJ, Wilson PW, Ohman EM, Brennan DM, D'Agostino RB, Bhatt DL, Steg PG. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010;31:1257-1265.
22. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol. 2007;100:1364-1369. (Pubitemid 47576015)
23. Giugliano RP, Giraldez RR, Morrow DA, Antman EM, Gibson CM, Mohanavelu S, Murphy SA, McCabe CH, Braunwald E. Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial. Eur Heart J. 2010;31: 2103-2110.